

Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Acute Lymphoblastic Leukemia, Large B-cell Lymphoma), By Vector Type (Lentivirus), By Region, And Segment Forecasts, 2023 - 2030

<https://marketpublishers.com/r/G3BCE840735EN.html>

Date: January 2023

Pages: 180

Price: US\$ 5,950.00 (Single User License)

ID: G3BCE840735EN

Abstracts

This report can be delivered to the clients within 2 Business Days

Gene Therapy Market Growth & Trends

The global gene therapy market is expected to reach USD 29.47 billion by 2030, registering a CAGR of 19.1% from 2023 to 2030, according to a new report by Grand View Research, Inc. The development of the market is owing to an increase in the number of gene therapy-based discoveries, increasing investment in this sector, and rising approval of gene therapy products. According to the WHO, 10 to 20 new cell and gene therapies are expected to be approved each year by 2025.

Continuous developments in recombinant DNA technology are anticipated to enhance the efficiency of gene therapy in the coming years. Hence, ongoing progresses in recombinant DNA technology are anticipated to expand the number of ongoing clinical trials for gene therapy. Primarily, these advancements are taking place in the context of various gene-editing tools and expression systems to augment the R&D for products. The advent of CRISPR/Cas9 nuclease, ZFN, and TALEN allows easy & precise genome editing. As a result, in recent times, the gene-editing space has witnessed a substantial number of research activities, which, in turn, is expected to influence the growth of the gene therapy market.

The growth of the gene therapy market is expected to be majorly benefitted from the increasing prevalence of cancer. The ongoing increase in cancer patients and related

death per year emphasizes the essential for the development of robust treatment solutions. In 2020, there were around 18.1 million new cases of cancer worldwide. 9.3 million of these cases involved men, while 8.8 million involved women. Continuing developments in tumor genetic studies have delivered substantial information about cancer-related molecular signatures, which in turn, is expected to support ongoing clinical trials for cancer therapeutics.

With rising demand for robust disease treatment therapies, companies have focused their efforts to accelerate R&D for effective genetic therapies that target the cause of disease at a genomic level. . Furthermore, the U.S. FDA provides constant support for innovations in this sector via a number of policies with regard to product manufacturing. In January 2020, the agency released six final guidelines on the manufacturing and clinical development of safe and efficient products.

Furthermore, facility expansion for cell and gene therapies is one of the major factors driving the gene therapy market growth. Several in-house facilities and CDMOs for gene therapy manufacturing have begun investing to enhance their production capacity, which, in turn, is anticipated to create lucrative opportunities for market players. For instance, in April 2022, the FDA approved commercial licensure approval to Novartis for its Durham, N.C. site. This approval permits the 170,000 square-foot facility to make, test, and issue commercial Zolgensma, as well as manufacture therapy products for current & upcoming clinical trials.

Gene Therapy Market Report Highlights

By vector type, the AAV segment is expected to grow rapidly during the forecast period. AAV is a popular vector for gene therapy, which accounts for a 24.0% share of the viral-vectored gene therapy studies conducted globally. During the last period, the number of clinical studies using AAV vectors has expanded swiftly

Moreover, Retroviruses held a significant market share in 2022 owing to the ease of isolation and incorporation of DNA into the virus

By indication, Spinal Muscular Atrophy (SMA) dominated the market. The development of Zolgensma has significantly proven its efficacy in the treatment of SMA, along with changing the disease phenotype. In May 2019, Novartis received approval from the FDA for Zolgensma, which is designed to address the root cause of SMA

The inherited retinal diseases segment is expected to expand at the fastest CAGR in the forecast period owing to the increase in R&D activities for the development of genetic therapies used for treating ocular diseases, including inherited retinal disease. Luxturna is being commercialized by Spark therapeutics in the U.S. and by Novartis outside the U.S. as a treatment for a form of inherited retinal disease

North America is a leading market in terms of revenue generated through clinical trials and a list of approved products. Considering factors such as a strong regulatory framework for stimulating the development of cellular therapy and the presence of a substantial number of biotechnology companies in the region, several sponsors and government agencies are making major investments

Asia Pacific is anticipated to witness significant growth in the forecast period, which can be attributed to growing adoption rate of the genetic therapies, increased investment by the governments, and presence of key companies

Contents

CHAPTER 1 EXECUTIVE SUMMARY

1.1 Market Summary

CHAPTER 2 RESEARCH METHODOLOGY

2.1 Information Procurement

2.2 Information or Data Analysis

2.3 Market Model

2.3.1 Historic And Base Year Estimates

2.3.2 Forecast Analysis

2.3.3 Study Of Approved Therapies By Disease Incidence

2.3.4 Study Of Approved Therapies By Vector

2.3.5 Region-Wise Approval

CHAPTER 3 MARKET VARIABLES, TRENDS, & SCOPE

3.1 Market Trends & Outlook

3.2 Market Segmentation

3.3 Market Dynamics

3.3.1 Market Driver Analysis

3.3.1.1 Robust Gene Therapy Pipeline

3.3.1.2 Introduction Of Technological Advancements

3.3.1.3 Increasing Investment From Companies And Partnerships

3.3.1.4 Growing Prevalence Of Target Diseases And Increased Demand For

Innovative Medicine

3.3.2 Market Restraint Analysis

3.3.2.1 Absence Of Effective Diagnosis Framework

3.3.2.2 High Prices Of Gene Therapy

3.3.3 Market Opportunity Analysis

3.3.3.1 Rising Investment For Adoptive T-Cell Transfer Approaches Of Disease

Treatment

3.3.3.2 Facility Expansion For Cell And Gene Therapies

3.3.3.3 Technological Advancements In Manufacturing Vectors

3.3.4 Challenge Analysis

3.3.4.1 Production capacity challenges

3.3.4.2 Manufacturing challenges about large-scale production of vectors

- 3.4 Regulatory Framework
- 3.5 Major Deals & Strategic Alliances Analysis
 - 3.5.1 Mergers & Acquisitions
 - 3.5.2 Collaborations & Partnerships
- 3.6 Pipeline Analysis
- 3.7 Payment & Pricing Models
 - 3.7.1 Payment Models For Innovative Therapies
- 3.8 Swot Analysis, by factor (Political & legal, economic, and technological)
- 3.9 Porter's Five Forces Analysis
- 3.10 Number of Gene Therapy Doses Sold in 2022
- 3.11 Number of Patients Treated with Gene Therapy, 2022

CHAPTER 4 COVID-19 IMPACT ANALYSIS

- 4.1 Key Market Initiatives
- 4.2 Conclusion

CHAPTER 5 INDICATION BUSINESS ANALYSIS

- 5.1 Gene Therapy Market: Indication Movement Analysis
- 5.2 Acute Lymphoblastic Leukemia (ALL)
 - 5.2.1 Global Gene Therapy Market For Acute Lymphoblastic Leukemia (All), 2018 - 2030 (USD Million)
 - 5.2.2 Global Acute Lymphoblastic Leukemia (All) Patients Treated With Gene Therapy, 2018 - 2030
- 5.3 Inherited Retinal Disease
 - 5.3.1 Global Gene Therapy Market For Inherited Retinal Disease, 2018 - 2030 (USD Million)
 - 5.3.2 Global Inherited Retinal Disease Patients Treated With Gene Therapy, 2018 - 2030
- 5.4 Large B-Cell Lymphoma
 - 5.4.1 Global Gene Therapy Market For Large B-Cell Lymphoma, 2018 - 2030 (USD Million)
 - 5.4.2 Global Large B-Cell Lymphoma Patients Treated With Gene Therapy, 2018 - 2030
- 5.5 Adenosine Deaminase (Ada)?Deficient Severe Combined Immunodeficiency (Scid)
 - 5.5.1 Global Gene Therapy Market For Ada-Scid, 2018 - 2030 (USD Million)
 - 5.5.2 Global Ada-Scid Patients Treated With Gene Therapy, 2018 - 2030
- 5.6 Melanoma (Lesions)

5.6.1 Global Gene Therapy Market For Melanoma (Lesions), 2018 - 2030 (USD Million)

5.6.2 Global Melanoma (Lesions) Patients Treated With Gene Therapy, 2018 - 2030

5.7 Beta-Thalassemia Major/Sickle Cell Disease (Scd)

5.7.1 Global Gene Therapy Market For Beta Thalassemia Major/Sickle Cell Diseases, 2018 - 2030 (USD Million)

5.7.2 Global Beta Thalassemia Major/Sickle Cell Diseases Patients Treated With Gene Therapy, 2018 - 2030

5.8 Head & Neck Squamous Cell Carcinoma

5.8.1 Global Gene Therapy Market For Head & Neck Squamous Cell Carcinoma, 2018 - 2030 (USD Million)

5.8.2 Global Head & Neck Squamous Cell Carcinoma Patients Treated With Gene Therapy, 2018 - 2030

5.9 Peripheral Arterial Disease

5.9.1 Global Gene Therapy Market For Peripheral Arterial Disease, 2018 - 2030 (USD Million)

5.9.2 Global Peripheral Arterial Disease Patients Treated With Gene Therapy, 2018 - 2030

5.10 Spinal Muscular Atrophy (Sma)

5.10.1 Global Gene Therapy Market For Spinal Muscular Atrophy (Sma), 2018 - 2030 (USD Million)

5.10.2 Global Spinal Muscular Atrophy (Sma) Patients Treated With Gene Therapy, 2018 - 2030

5.11 Others

CHAPTER 6 VECTOR TYPE BUSINESS ANALYSIS

6.1 Gene Therapy Market: Vector Type Movement Analysis

6.2 Gene Therapy Market: Vector Movement Analysis

6.3 Lentiviral Vectors

6.3.1 Global Lentivirus-Based Gene Therapy Market, 2018 - 2030 (USD Million)

6.4 Adeno-Associated Viral (Aav) Vectors

6.4.1 Global Aav-Based Gene Therapy Market, 2018 - 2030 (USD Million)

6.5 Retrovirus Vectors

6.5.1 Global Retrovirus Vectors-Based Gene Therapy Market, 2018 - 2030 (USD Million)

6.6 Modified Herpes Simplex Virus

6.6.1 Global Modified Herpes Simplex Virus Vectors -Based Gene Therapy Market, 2018 - 2030 (USD Million)

6.7 Adenovirus Vectors

6.7.1 Global Adenovirus Vectors-Based Gene Therapy Market, 2018 - 2030 (USD Million)

6.8 Non-Viral Plasmid Vector

6.8.1 Global Non-Viral Plasmid Vector-Based Gene Therapy Market, 2018 - 2030 (USD Million)

6.9 Others

6.9.1 Global Others-Based Gene Therapy Market, 2018 - 2030 (USD Million)

CHAPTER 7 REGIONAL BUSINESS ANALYSIS

7.1 North America

7.1.1 Swot Analysis

7.1.1.1 North America Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.1.2 U.S.

7.1.2.1 Key Country Dynamics

7.1.2.2 Target Disease Prevalence

7.1.2.3 Competitive Scenario

7.1.2.4 Regulatory Framework

7.1.2.5 Reimbursement Scenario

7.1.2.6 U.S. Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.1.3 Canada

7.1.3.1 Key Country Dynamics

7.1.3.2 Target Disease Prevalence

7.1.3.3 Competitive Scenario

7.1.3.4 Regulatory Framework

7.1.3.5 Reimbursement Scenario

7.1.3.6 Canada Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.2 Europe

7.2.1 Swot Analysis

7.2.1.1 Europe Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.2.2 Germany

7.2.2.1 Key Country Dynamics

7.2.2.2 Target Disease Prevalence

7.2.2.3 Competitive Scenario

7.2.2.4 Regulatory Framework

7.2.2.5 Reimbursement Scenario

7.2.2.6 Germany Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.2.3 U.K.

7.2.3.1 Key Country Dynamics

7.2.3.2 Target Disease Prevalence

7.2.3.3 Competitive Scenario

7.2.3.4 Regulatory Framework

7.2.3.5 Reimbursement Scenario

7.2.3.6 UK Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.2.4 France

7.2.4.1 Key Country Dynamics

7.2.4.2 Target Disease Prevalence

7.2.4.3 Competitive Scenario

7.2.4.4 Regulatory Framework

7.2.4.5 Reimbursement Scenario

7.2.4.6 France Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.2.5 Italy

7.2.5.1 Key Country Dynamics

7.2.5.2 Target Disease Prevalence

7.2.5.3 Competitive Scenario

7.2.5.4 Regulatory Framework

7.2.5.5 Reimbursement Scenario

7.2.5.6 Italy Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.2.6 Spain

7.2.6.1 Key Country Dynamics

7.2.6.2 Target Disease Prevalence

7.2.6.3 Competitive Scenario

7.2.6.4 Regulatory Framework

7.2.6.5 Reimbursement Scenario

7.2.6.6 Spain Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)

7.2.7 Denmark

7.2.7.1 Key Country Dynamics

7.2.7.2 Target Disease Prevalence

7.2.7.3 Competitive Scenario

7.2.7.4 Regulatory Framework

7.2.7.5 Reimbursement Scenario

7.2.7.6 Denmark Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.2.8 Sweden

7.2.8.1 Key Country Dynamics

7.2.8.2 Target Disease Prevalence

7.2.8.3 Competitive Scenario

7.2.8.4 Regulatory Framework

7.2.8.5 Reimbursement Scenario

7.2.8.6 Sweden Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.2.9 Norway

7.2.9.1 Key Country Dynamics

7.2.9.2 Target Disease Prevalence

7.2.9.3 Competitive Scenario

7.2.9.4 Regulatory Framework

7.2.9.5 Reimbursement Scenario

7.2.9.6 Norway Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.2.10 Rest Of Europe Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.3 Asia Pacific

7.3.1 Swot Analysis

7.3.1.1 Key Region Dynamics

7.3.1.2 Asia Pacific Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.3.2 Japan

7.3.2.1 Target Disease Prevalence

7.3.2.2 Competitive Scenario

7.3.2.3 Regulatory Framework

7.3.2.4 Reimbursement Scenario

7.3.2.5 Japan Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.3.3 China

7.3.3.1 Target Disease Prevalence

7.3.3.2 Competitive Scenario

7.3.3.3 Regulatory Framework

7.3.3.4 Reimbursement Scenario

7.3.3.5 China Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.3.4 India

7.3.4.1 Target Disease Prevalence

7.3.4.2 Competitive Scenario

7.3.4.3 Regulatory Framework

7.3.4.4 Reimbursement Scenario

7.3.4.5 India Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.3.5 South Korea

7.3.5.1 Target Disease Prevalence

7.3.5.2 Competitive Scenario

7.3.5.3 Regulatory Framework

7.3.5.4 Reimbursement Scenario

7.3.5.5 South Korea Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.3.6 Australia

7.3.6.1 Target Disease Prevalence

7.3.6.2 Competitive Scenario

7.3.6.3 Regulatory Framework

7.3.6.4 Reimbursement Scenario

7.3.6.5 Australia Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.3.7 Thailand

7.3.7.1 Target Disease Prevalence

7.3.7.2 Competitive Scenario

7.3.7.3 Regulatory Framework

7.3.7.4 Reimbursement Scenario

7.3.7.5 Thailand Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.3.8 Rest Of Asia Pacific Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)

7.4 Latin America

7.4.1 Swot Analysis:

7.4.2 Key Regional Dynamics

7.4.2.1 Latin America Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.4.3 Brazil

7.4.3.1 Target Disease Prevalence

7.4.3.2 Competitive Scenario

7.4.3.3 Regulatory Framework

7.4.3.4 Reimbursement Scenario

7.4.3.5 Brazil Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.4.4 Mexico

7.4.4.1 Target Disease Prevalence

7.4.4.2 Competitive Scenario

7.4.4.3 Regulatory Framework

7.4.4.4 Reimbursement Scenario

7.4.4.5 Mexico Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.4.5 Argentina

7.4.5.1 Target Disease Prevalence

7.4.5.2 Competitive Scenario

7.4.5.3 Regulatory Framework

7.4.5.4 Reimbursement Scenario

7.4.5.5 Argentina Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.4.6 Colombia

7.4.6.1 Target Disease Prevalence

7.4.6.2 Competitive Scenario

7.4.6.3 Regulatory Framework

7.4.6.4 Reimbursement Scenario

7.4.6.5 Colombia Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.4.7 Chile

7.4.7.1 Target Disease Prevalence

7.4.7.2 Competitive Scenario

7.4.7.3 Regulatory Framework

7.4.7.4 Reimbursement Scenario

7.4.7.5 Chile Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.4.8 Rest Of Latam Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)

7.5 Middle East & Africa (MEA)

7.5.1 Swot Analysis

7.5.2 Key Regional Dynamics

7.5.2.1 Middle East & Africa Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.5.3 South Africa

7.5.3.1 Target Disease Prevalence

7.5.3.2 Competitive Scenario

7.5.3.3 Regulatory Framework

7.5.3.4 Reimbursement Scenario

7.5.3.5 South Africa Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.5.4 Saudi Arabia

7.5.4.1 Target Disease Prevalence

7.5.4.2 Competitive Scenario

7.5.4.3 Regulatory Framework

7.5.4.4 Reimbursement Scenario

7.5.4.5 Saudi Arabia Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.5.5 UAE

7.5.5.1 Target Disease Prevalence

7.5.5.2 Competitive Scenario

7.5.5.3 Regulatory Framework

7.5.5.4 Reimbursement Scenario

7.5.5.5 UAE Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.5.6 Israel

7.5.6.1 Target Disease Prevalence

7.5.6.2 Competitive Scenario

7.5.6.3 Regulatory Framework

7.5.6.4 Reimbursement Scenario

7.5.6.5 Israel Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.5.7 Egypt

7.5.7.1 Target Disease Prevalence

7.5.7.2 Competitive Scenario

7.5.7.3 Regulatory Framework

7.5.7.4 Reimbursement Scenario

7.5.7.5 Egypt Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.5.8 Kuwait

7.5.8.1 Target Disease Prevalence

- 7.5.8.2 Competitive Scenario
- 7.5.8.3 Regulatory Framework
- 7.5.8.4 Reimbursement Scenario
- 7.5.8.5 Kuwait Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.9 Rest of MEA Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

CHAPTER 8 COMPANY PROFILES

8.1 Company Profiles

8.1.1 REGENXBIO, INC.

- 8.1.1.1 Company overview
- 8.1.1.2 Financial performance
- 8.1.1.3 Product benchmarking
- 8.1.1.4 Strategic Initiatives

8.1.2 OXFORD BIOMEDICA PLC

- 8.1.2.1 Company overview
- 8.1.2.2 Financial performance
- 8.1.2.3 Product benchmarking
- 8.1.2.4 Strategic Initiatives

8.1.3 VOYAGER THERAPEUTICS

- 8.1.3.1 Company overview
- 8.1.3.2 Financial performance
- 8.1.3.3 Product benchmarking
- 8.1.3.4 Strategic Initiatives

8.1.4 HUMAN STEM CELLS INSTITUTE

- 8.1.4.1 Company overview
- 8.1.4.2 Product benchmarking
- 8.1.4.3 Strategic Initiatives

8.1.5 DIMENSION THERAPEUTICS, INC.

- 8.1.5.1 Company overview
- 8.1.5.2 Financial performance
- 8.1.5.3 Product benchmarking
- 8.1.5.4 Strategic Initiatives

8.1.6 BRISTOL-MYERS SQUIBB COMPANY

- 8.1.6.1 Company overview
 - 8.1.6.1.1 Celgene Corporation
- 8.1.6.2 Financial performance (Bristol-Myers Squibb)

- 8.1.6.2.1 Financial performance (Celgene Corporation)
- 8.1.6.3 Product benchmarking (Bristol-Myers Squibb)
 - 8.1.6.3.1 Product benchmarking (Celgene)
- 8.1.6.4 Strategic Initiatives
 - 8.1.6.4.1 Strategic Initiatives
- 8.1.7 SANOFI
 - 8.1.7.1 Company overview
 - 8.1.7.2 Financial performance
 - 8.1.7.3 Product benchmarking
 - 8.1.7.4 Strategic Initiatives
- 8.1.8 APPLIED GENETIC TECHNOLOGIES CORPORATION
 - 8.1.8.1 Company overview
 - 8.1.8.2 Financial performance
 - 8.1.8.3 Product benchmarking
 - 8.1.8.4 Strategic Initiatives
- 8.1.9 F. HOFFMANN-LA ROCHE LTD.
 - 8.1.9.1 Company overview
 - 8.1.9.1.1 Spark Therapeutics, Inc.
 - 8.1.9.2 Financial performance
 - 8.1.9.3 Product benchmarking
 - 8.1.9.4 Strategic Initiatives
- 8.1.10 BLUEBIRD BIO, INC.
 - 8.1.10.1 Company overview
 - 8.1.10.2 Financial performance
 - 8.1.10.3 Product benchmarking
 - 8.1.10.4 Strategic Initiatives
- 8.1.11 NOVARTIS AG
 - 8.1.11.1 Company overview
 - 8.1.11.1.1 AveXis, Inc.
 - 8.1.11.2 Financial performance
 - 8.1.11.3 Product benchmarking
 - 8.1.11.4 Strategic Initiatives
 - 8.1.11.4.1 Strategic Initiatives
- 8.1.12 TAXUS CARDIUM PHARMACEUTICALS GROUP, INC. (GENE BIOTHERAPEUTICS)
 - 8.1.12.1 Company overview
 - 8.1.12.2 Product benchmarking
 - 8.1.12.3 Strategic Initiatives
- 8.1.13 UNIQUIRE N.V.

- 8.1.13.1 Company overview
- 8.1.13.2 Financial performance
- 8.1.13.3 Product benchmarking
- 8.1.13.4 Strategic Initiatives
- 8.1.14 TAKEDA PHARMACEUTICAL COMPANY LIMITED
 - 8.1.14.1 Company overview
 - 8.1.14.2 Financial performance
 - 8.1.14.3 Product benchmarking
 - 8.1.14.4 Strategic Initiatives
- 8.1.15 CELLECTIS S.A.
 - 8.1.15.1 Company overview
 - 8.1.15.2 Financial performance
 - 8.1.15.3 Product benchmarking
 - 8.1.15.4 Strategic Initiatives
- 8.1.16 SANGAMO THERAPEUTICS, INC.
 - 8.1.16.1 Company overview
 - 8.1.16.2 Financial performance
 - 8.1.16.3 Product benchmarking
 - 8.1.16.4 Strategic Initiatives
- 8.1.17 ORCHARD THERAPEUTICS
 - 8.1.17.1 Company overview
 - 8.1.17.2 Financial performance
 - 8.1.17.3 Product benchmarking
 - 8.1.17.4 Strategic Initiatives
- 8.1.18 GILEAD LIFESCIENCES, INC.
 - 8.1.18.1 Company overview
 - 8.1.18.2 Financial Performance
 - 8.1.18.3 Product benchmarking
 - 8.1.18.4 Strategic Initiatives
- 8.1.19 BENITEC BIOPHARMA
 - 8.1.19.1 Company overview
 - 8.1.19.2 Financial Performance
 - 8.1.19.3 Product benchmarking
 - 8.1.19.4 Strategic Initiatives
- 8.1.20 SIBIONO GENETECH CO., LTD
 - 8.1.20.1 Company overview
 - 8.1.20.2 Product benchmarking
- 8.1.21 SHANGHAI SUNWAY BIOTECH CO., LTD.
 - 8.1.21.1 Company overview

- 8.1.21.2 Product benchmarking
- 8.1.22 GENSIGHT BIOLOGICS S.A.
 - 8.1.22.1 Company overview
 - 8.1.22.2 Financial performance
 - 8.1.22.3 Product benchmarking
 - 8.1.22.4 Strategic initiatives
- 8.1.23 TRANSGENE
 - 8.1.23.1 Company overview
 - 8.1.23.2 Financial performance
 - 8.1.23.3 Product benchmarking
 - 8.1.23.4 Strategic initiatives
- 8.1.24 CALIMMUNE, INC.
 - 8.1.24.1 Company overview
 - 8.1.24.2 Product benchmarking
 - 8.1.24.3 Strategic initiatives
- 8.1.25 EPEIUS BIOTECHNOLOGIES CORP.
 - 8.1.25.1 Company overview
 - 8.1.25.2 Product benchmarking
- 8.1.26 ASTELLAS PHARMA INC.
 - 8.1.26.1 Company overview
 - 8.1.26.2 Audentes Therapeutics, Inc.
 - 8.1.26.2.1 Company overview
 - 8.1.26.3 Financial performance
 - 8.1.26.3.1 Financial performance
 - 8.1.26.4 Product benchmarking
 - 8.1.26.5 Strategic initiatives
- 8.1.27 AMERICAN GENE TECHNOLOGIES
 - 8.1.27.1 Company overview
 - 8.1.27.2 Product benchmarking
 - 8.1.27.3 Strategic initiatives
- 8.1.28 BIOMARIN PHARMACEUTICALS, INC.
 - 8.1.28.1 Company overview
 - 8.1.28.2 Financial performance
 - 8.1.28.3 Product benchmarking
 - 8.1.28.4 Strategic initiatives

List Of Tables

LIST OF TABLES

Table 1 List of Secondary Sources

Table 2 List of Tables

Table 3 List of Secondary Sources

Table 4 List of Abbreviations

Table 5 Global Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)

Table 6 Global Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)

Table 7 Global Gene Therapy Market by Region, 2018 - 2030 (USD Million)

Table 8 North America Gene Therapy Market by Country, 2018 - 2030 (USD Million)

Table 9 North America Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)

Table 10 North America Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)

Table 11 U.S. Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)

Table 12 U.S. Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)

Table 13 Canada Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)

Table 14 Canada Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)

Table 15 Europe Gene Therapy Market by Country, 2018 - 2030 (USD Million)

Table 16 Europe Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)

Table 17 Europe Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)

Table 18 Germany Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)

Table 19 Germany Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)

Table 20 U.K. Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)

Table 21 U.K. Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)

Table 22 France Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)

Table 23 France Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)

Table 24 Italy Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)

Table 25 Italy Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)

- Table 26 Spain Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
- Table 27 Spain Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)
- Table 28 Denmark Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
- Table 29 Denmark Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)
- Table 30 Sweden Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
- Table 31 Sweden Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)
- Table 32 Norway Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
- Table 33 Norway Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)
- Table 34 Asia Pacific Gene Therapy Market by Country, 2018 - 2030 (USD Million)
- Table 35 Asia Pacific Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
- Table 36 Asia Pacific Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)
- Table 37 China Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
- Table 38 China Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)
- Table 39 Japan Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
- Table 40 Japan Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)
- Table 41 India Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
- Table 42 India Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)
- Table 43 South Korea Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
- Table 44 South Korea Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)
- Table 45 Australia Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
- Table 46 Australia Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)
- Table 47 Thailand Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
- Table 48 Thailand Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)
- Table 49 Latin America Gene Therapy Market by Country, 2018 - 2030 (USD Million)
- Table 50 Latin America Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
- Table 51 Latin America Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)

- Table 52 Brazil Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
- Table 53 Brazil Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)
- Table 54 Mexico Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
- Table 55 Mexico Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)
- Table 56 Argentina Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
- Table 57 Argentina Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)
- Table 58 Colombia Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
- Table 59 Colombia Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)
- Table 60 Chile Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
- Table 61 Chile Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)
- Table 62 Middle East & Africa Gene Therapy Market by Country, 2018 - 2030 (USD Million)
- Table 63 Middle East & Africa Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
- Table 64 Middle East & Africa Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)
- Table 65 South Africa Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
- Table 66 South Africa Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)
- Table 67 Saudi Arabia Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
- Table 68 Saudi Arabia Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)
- Table 69 UAE Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
- Table 70 UAE Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)
- Table 71 Israel Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
- Table 72 Israel Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)
- Table 73 Egypt Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
- Table 74 Egypt Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)
- Table 75 Kuwait Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
- Table 76 Kuwait Gene Therapy Market by Indication, 2018 - 2030 (USD Million) (Number of patients treated with gene therapy)

List Of Figures

LIST OF FIGURES

- Fig. 1 Information Procurement
- Fig. 2 Primary Research Pattern
- Fig. 3 Market Research Approaches
- Fig. 4 Value Chain-Based Sizing & Forecasting
- Fig. 5 Market Formulation & Validation
- Fig. 6 Gene Therapy Market Segmentation
- Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
- Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
- Fig. 9 Market Challenge Relevance Analysis (Current & Future Impact)
- Fig. 10 Penetration & Growth Prospect Mapping
- Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
- Fig. 12 Porter's Five Forces Analysis
- Fig. 13 Market Penetration Vs Growth Prospect Mapping, 2022
- Fig. 14 Number of gene therapy doses sold in 2022
- Fig. 15 Patients treated with gene therapy in 2022
- Fig. 16 Regional Marketplace: Key Takeaways
- Fig. 17 Global Gene Therapy Market for Lentivirus, 2018 - 2030 (USD Million)
- Fig. 18 Global Gene Therapy Market for AAV, 2018 - 2030 (USD Million)
- Fig. 19 Global Gene Therapy Market for RetroVirus & gamma RetroVirus, 2018 - 2030 (USD Million)
- Fig. 20 Global Gene Therapy Market for Modified Herpes Simplex Virus, 2018 - 2030 (USD Million)
- Fig. 21 Global Gene Therapy Market for Adenovirus, 2018 - 2030 (USD Million)
- Fig. 22 Global Gene Therapy Market for Non-viral Plasmid Vector, 2018 - 2030 (USD Million)
- Fig. 23 Global Gene Therapy Market for Other Vector Type, 2018 - 2030 (USD Million)
- Fig. 24 Global Gene Therapy Market for Acute Lymphoblastic Leukemia (ALL), 2018 - 2030 (USD Million)
- Fig. 25 Global Acute Lymphoblastic Leukemia (ALL) patients treated with gene therapy, 2018 - 2030
- Fig. 26 Global Gene Therapy Market for Inherited Retinal Disease, 2018 - 2030 (USD Million)
- Fig. 27 Global Inherited Retinal Disease patients treated with gene therapy, 2018 - 2030
- Fig. 28 Global Gene Therapy Market for Large B-cell Lymphoma, 2018 - 2030 (USD Million)

- Fig. 29 Global Large B-cell Lymphoma patients treated with gene therapy, 2018 - 2030
- Fig. 30 Global Gene Therapy Market for ADA-SCID, 2018 - 2030 (USD Million)
- Fig. 31 Global ADA-SCID patients treated with gene therapy, 2018 - 2030
- Fig. 32 Global Gene Therapy Market for Melanoma (lesions), 2018 - 2030 (USD Million)
- Fig. 33 Global Melanoma (lesions) patients treated with gene therapy, 2018 - 2030
- Fig. 34 Global Gene Therapy Market for Beta-Thalassemia Major/SCD, 2018 - 2030 (USD Million)
- Fig. 35 Global Beta-Thalassemia Major/SCD patients treated with gene therapy, 2018 - 2030
- Fig. 36 Global Gene Therapy Market for Head & Neck Squamous Cell Carcinoma, 2018 - 2030 (USD Million)
- Fig. 37 Global Head & Neck Squamous Cell Carcinoma patients treated with gene therapy, 2018 - 2030
- Fig. 38 Global Gene Therapy Market for Peripheral arterial disease, 2018 - 2030 (USD Million)
- Fig. 39 Global Peripheral arterial disease patients treated with gene therapy, 2018 - 2030
- Fig. 40 Global Gene Therapy Market for Spinal Muscular Atrophy (SMA), 2018 - 2030 (USD Million)
- Fig. 41 Global Spinal Muscular Atrophy (SMA) patients treated with gene therapy, 2018 - 2030
- Fig. 42 Global Gene Therapy Market for Others, 2018 - 2030 (USD Million)
- Fig. 43 Global Other diseases patient treated with gene therapy, 2018 - 2030
- Fig. 44 Regional Outlook, 2022 & 2030
- Fig. 45 North America Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 46 U.S. Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 47 Canada Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 48 Europe Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 49 Germany Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 50 UK Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 51 France Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 52 Italy Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 53 Spain Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 54 Denmark Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 55 Sweden Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 56 Norway Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 57 Asia Pacific Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 58 Japan Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 59 China Gene Therapy Market, 2018 - 2030 (USD Million)

- Fig. 60 India Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 61 Australia Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 62 Thailand Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 63 South Korea Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 64 Latin America Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 65 Brazil Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 66 Mexico Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 67 Argentina Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 68 Colombia Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 69 Chile Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 70 Middle East and Africa Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 71 South Africa Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 72 Saudi Arabia Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 73 UAE Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 74 Israel Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 75 Egypt Gene Therapy Market, 2018 - 2030 (USD Million)
- Fig. 76 Kuwait Gene Therapy Market, 2018 - 2030 (USD Million)

I would like to order

Product name: Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Acute Lymphoblastic Leukemia, Large B-cell Lymphoma), By Vector Type (Lentivirus), By Region, And Segment Forecasts, 2023 - 2030

Product link: <https://marketpublishers.com/r/G3BCE840735EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3BCE840735EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970